Phase 2 Data Support TL1A Inhibition in RA, but Spyre Opts Against Monotherapy Priority
Spyre’s RA drug showed benefits and good safety, but results weren’t strong enough to justify developing it as a stand-alone treatment.
/ 3 items
#SYRE↓
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform on Valuation Concerns
Wolfe Research cuts Spyre Therapeutics from Outperform to Peer Perform, citing fair valuation ($96–$113) and weaker Q3 catalysts.
Spyre’s SPY001 Delivers Strong Early Results in Ulcerative Colitis Trial – Shares Jump
Spyre drug SPY001 showed strong IBD results, improving symptoms and remission in trials, boosting shares and future outlook.